HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albers, G. W. Search for Related Content PubMed PubMed Citation Articles by Albers, G. W.

Advances in intravenous thrombolytic therapy for treatment of acute stroke

From the Stanford Stroke Center, Palo Alto, California.

Address correspondence and reprint requests to Dr. Gregory W. Albers, Director, Stanford Stroke Center, Stanford University Medical Center, 701 Welch Road, Suite 235, Palo Alto, CA 94304.

Intravenous tissue plasminogen activator (tPA) is an effective therapy for treatment of acute ischemic stroke when administered within 3 hours of symptom onset. Three large randomized clinical trials that have attempted to extend the time window for tPA treatment beyond 3 hours have failed to demonstrate convincing evidence of efficacy. A recently published prospective, monitored, multicenter study of 389 patients, who were treated with tPA for ischemic stroke at 57 medical centers (24 academic, 33 community) across the United States, demonstrated favorable outcomes and low rates of symptomatic intracerebral hemorrhage. Recent advances in neuroimaging, including diffusion-weighted MRI (DWI) and perfusion-weighted MRI (PWI), have the potential to differentiate salvageable ischemic brain tissue from irreversibly injured tissue. Preliminary data suggest that acute stroke patients who present with a PWI lesion that is considerably larger than the initial DWI lesion may be good candidates for intravenous thrombolysis, even beyond 3 hours after symptom onset. Additional research is required to clarify the optimal use of these diagnostic techniques and their cost-effectiveness.

This article has been cited by other articles:

				H. J. Audebert, C. Kukla, S. Clarmann von Claranau, J. Kuhn, B. Vatankhah, J. Schenkel, G. W. Ickenstein, R. L. Haberl, M. Horn, and on behalf of the TEMPiS Group Telemedicine for Safe and Extended Use of Thrombolysis in Stroke: The Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria Stroke, February 1, 2005; 36(2): 287 - 291. [Abstract] [Full Text] [PDF]

				U. G. Schulz, D. Briley, T. Meagher, A. Molyneux, and P. M. Rothwell Diffusion-Weighted MRI in 300 Patients Presenting Late With Subacute Transient Ischemic Attack or Minor Stroke Stroke, November 1, 2004; 35(11): 2459 - 2465. [Abstract] [Full Text] [PDF]

				J. Fiehler, K. Knudsen, T. Kucinski, C. S. Kidwell, J. R. Alger, G. Thomalla, B. Eckert, O. Wittkugel, C. Weiller, H. Zeumer, et al. Predictors of Apparent Diffusion Coefficient Normalization in Stroke Patients Stroke, February 1, 2004; 35(2): 514 - 519. [Abstract] [Full Text] [PDF]